SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bellamy, W. T. Articles by List, A. F. Search for Related Content PubMed PubMed Citation Articles by Bellamy, W. T. Articles by List, A. F. Related Collections Neoplasia Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 March 2001, Vol. 97, No. 5, pp. 1427-1434 NEOPLASIA Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes William T. Bellamy, Lynne Richter, Davuud Sirjani, Concepcion Roxas, Betty Glinsmann-Gibson, Yvette Frutiger, Thomas M. Grogan, and Alan F. List From the Department of Pathology, the Department of Hematology/Oncology, and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson, AZ. Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of hematopoietic stem cell development, extracellular matrix remodeling, and inflammatory cytokine generation. To delineate the potential role of VEGF in patients with myelodysplastic syndrome (MDS), VEGF protein and receptor expression and its functional significance in MDS bone marrow (BM) were evaluated. In BM clot sections from normal donors, low-intensity cytoplasmic VEGF expression was detected infrequently in isolated myeloid elements. However, monocytoid precursors in chronic myelomonocytic leukemia (CMML) expressed VEGF in an intense cytoplasmic pattern with membranous co-expression of the Flt-1 or KDR receptors, or both. In situ hybridization confirmed the presence of VEGF mRNA in the neoplastic monocytes. In acute myelogenous leukemia (AML) and other MDS subtypes, intense co-expression of VEGF and one or both receptors was detected in myeloblasts and immature myeloid elements, whereas erythroid precursors and lymphoid cells lacked VEGF and receptor expression. Foci of abnormal localized immature myeloid precursors (ALIP) co-expressed VEGF and Flt-1 receptor, suggesting autocrine cytokine interaction. Antibody neutralization of VEGF inhibited colony-forming unit (CFU)-leukemia formation in 9 of 15 CMML and RAEB-t patient specimens, whereas VEGF stimulated leukemia colony formation in 12 patients. Neutralization of VEGF activity suppressed the generation of tumor necrosis factor- and interleukin-1 from MDS BM-mononuclear cells and BM-stroma and promoted the formation of CFU-GEMM and burst-forming unit-erythroid in methylcellulose cultures. These findings indicate that autocrine production of VEGF may contribute to leukemia progenitor self-renewal and inflammatory cytokine elaboration in CMML and MDS and thus provide a biologic rationale for ALIP and its adverse prognostic relevance in high-risk MDS. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Letter in Blood Online: Misleading information about ALIP and VEGF in myelodysplasia Manzoor H. Mangi, William T. Bellamy, Thomas M. Grogan, and Alan F. List Blood 2001 98: 1272-1273. [Full Text] [PDF] This article has been cited by other articles: S. Monteghirfo, F. Tosetti, C. Ambrosini, S. Stigliani, S. Pozzi, F. Frassoni, G. Fassina, S. Soverini, A. Albini, and N. Ferrari Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-{kappa}B and p53 modulation Mol. Cancer Ther., September 1, 2008; 7(9): 2692 - 2702. [Abstract] [Full Text] [PDF] A. M. Marcondes, A. J. Mhyre, D. L. Stirewalt, S.-H. Kim, C. A. Dinarello, and H. J. Deeg Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function PNAS, February 26, 2008; 105(8): 2865 - 2870. [Abstract] [Full Text] [PDF] H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5544s - 5548s. [Abstract] [Full Text] [PDF] S. Pillozzi, M. F. Brizzi, P. A. Bernabei, B. Bartolozzi, R. Caporale, V. Basile, V. Boddi, L. Pegoraro, A. Becchetti, and A. Arcangeli VEGFR-1 (FLT-1), {beta}1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome Blood, August 15, 2007; 110(4): 1238 - 1250. [Abstract] [Full Text] [PDF] Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood, July 15, 2007; 110(2): 624 - 631. [Abstract] [Full Text] [PDF] P. D. Jani, N. Singh, C. Jenkins, S. Raghava, Y. Mo, S. Amin, U. B. Kompella, and B. K. Ambati Nanoparticles Sustain Expression of Flt Intraceptors in the Cornea and Inhibit Injury-Induced Corneal Angiogenesis Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2030 - 2036. [Abstract] [Full Text] [PDF] N. Singh, P. D. Jani, T. Suthar, S. Amin, and B. K. Ambati Flt-1 Intraceptor Induces the Unfolded Protein Response, Apoptotic Factors, and Regression of Murine Injury-Induced Corneal Neovascularization Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4787 - 4793. [Abstract] [Full Text] [PDF] R. Kim, M. Emi, K. Tanabe, and K. Arihiro Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression Cancer Res., June 1, 2006; 66(11): 5527 - 5536. [Abstract] [Full Text] [PDF] R. Fragoso, T. Pereira, Y. Wu, Z. Zhu, J. Cabecadas, and S. Dias VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease Blood, February 15, 2006; 107(4): 1608 - 1616. [Abstract] [Full Text] [PDF] B. Larrivee, I. Pollet, and A. Karsan Activation of Vascular Endothelial Growth Factor Receptor-2 in Bone Marrow Leads to Accumulation of Myeloid Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor J. Immunol., September 1, 2005; 175(5): 3015 - 3024. [Abstract] [Full Text] [PDF] B. Das, H. Yeger, R. Tsuchida, R. Torkin, M. F.W. Gee, P. S. Thorner, M. Shibuya, D. Malkin, and S. Baruchel A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1{alpha} through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma Cancer Res., August 15, 2005; 65(16): 7267 - 7275. [Abstract] [Full Text] [PDF] M. Chavez-MacGregor, A. Aviles-Salas, D. Green, A. Fuentes-Alburo, C. Gomez-Ruiz, and A. Aguayo Angiogenesis in the Bone Marrow of Patients with Breast Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5396 - 5400. [Abstract] [Full Text] [PDF] N. Singh, S. Amin, E. Richter, S. Rashid, V. Scoglietti, P. D. Jani, J. Wang, R. Kaur, J. Ambati, Z. Dong, et al. Flt-1 Intraceptors Inhibit Hypoxia-Induced VEGF Expression In Vitro and Corneal Neovascularization In Vivo Invest. Ophthalmol. Vis. Sci., May 1, 2005; 46(5): 1647 - 1652. [Abstract] [Full Text] [PDF] A. List, S. Kurtin, D. J. Roe, A. Buresh, D. Mahadevan, D. Fuchs, L. Rimsza, R. Heaton, R. Knight, and J. B. Zeldis Efficacy of Lenalidomide in Myelodysplastic Syndromes N. Engl. J. Med., February 10, 2005; 352(6): 549 - 557. [Abstract] [Full Text] [PDF] D. Mahadevan and A. F. List Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies Blood, October 1, 2004; 104(7): 1940 - 1951. [Abstract] [Full Text] [PDF] J. L. Liesveld, C. T. Jordan, and G. L. Phillips II The Hematopoietic Stem Cell in Myelodysplasia Stem Cells, July 1, 2004; 22(4): 590 - 599. [Abstract] [Full Text] [PDF] J. E. Karp, I. Gojo, R. Pili, C. D. Gocke, J. Greer, C. Guo, D. Qian, L. Morris, M. Tidwell, H. Chen, et al. Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-{beta}-D-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab Clin. Cancer Res., June 1, 2004; 10(11): 3577 - 3585. [Abstract] [Full Text] [PDF] H. X. Chen Expanding the Clinical Development of Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 27 - 35. [Abstract] [Full Text] [PDF] S. C. R. Santos and S. Dias Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways Blood, May 15, 2004; 103(10): 3883 - 3889. [Abstract] [Full Text] [PDF] A. F. List, J. Vardiman, J.-P. J. Issa, and T. M. DeWitte Myelodysplastic Syndromes Hematology, January 1, 2004; 2004(1): 297 - 317. [Abstract] [Full Text] [PDF] R. Zheng, M. Levis, O. Piloto, P. Brown, B. R. Baldwin, N. C. Gorin, M. Beran, Z. Zhu, D. Ludwig, D. Hicklin, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells Blood, January 1, 2004; 103(1): 267 - 274. [Abstract] [Full Text] [PDF] J. E. Lancet and J. E. Karp Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy Blood, December 1, 2003; 102(12): 3880 - 3889. [Abstract] [Full Text] [PDF] G. Mufti, A. F. List, S. D. Gore, and A. Y.L. Ho Myelodysplastic Syndrome Hematology, January 1, 2003; 2003(1): 176 - 199. [Abstract] [Full Text] [PDF] M. Mayerhofer, P. Valent, W. R. Sperr, J. D. Griffin, and C. Sillaber BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha , through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin Blood, November 15, 2002; 100(10): 3767 - 3775. [Abstract] [Full Text] [PDF] S. J. Welsh, W. T. Bellamy, M. M. Briehl, and G. Powis The Redox Protein Thioredoxin-1 (Trx-1) Increases Hypoxia-inducible Factor 1{alpha} Protein Expression: Trx-1 Overexpression Results in Increased Vascular Endothelial Growth Factor Production and Enhanced Tumor Angiogenesis Cancer Res., September 1, 2002; 62(17): 5089 - 5095. [Abstract] [Full Text] [PDF] A. Stopeck, M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia, and A. Hannah Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies Clin. Cancer Res., September 1, 2002; 8(9): 2798 - 2805. [Abstract] [Full Text] [PDF] A. F. List New Approaches to the Treatment of Myelodysplasia Oncologist, April 1, 2002; 7(90001): 39 - 49. [Abstract] [Full Text] [PDF] G. J. Bauerschmitz, D. M. Nettelbeck, A. Kanerva, A. H. Baker, A. Hemminki, P. N. Reynolds, and D. T. Curiel The flt-1 Promoter for Transcriptional Targeting of Teratocarcinoma Cancer Res., March 1, 2002; 62(5): 1271 - 1274. [Abstract] [Full Text] [PDF] P. L. Greenberg, N. S. Young, and N. Gattermann Myelodysplastic Syndromes Hematology, January 1, 2002; 2002(1): 136 - 161. [Abstract] [Full Text] A. F. List, K. J. Kopecky, C. L. Willman, D. R. Head, D. L. Persons, M. L. Slovak, R. Dorr, C. Karanes, H. E. Hynes, J. H. Doroshow, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood, December 1, 2001; 98(12): 3212 - 3220. [Abstract] [Full Text] [PDF] A. F. List Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies Oncologist, October 1, 2001; 6(2008): 24 - 31. [Abstract] [Full Text] [PDF] A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, F. Nascimben, M. du Randt, C. Kaspar, C. Goldberg, J. Loew, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes Blood, August 15, 2001; 98(4): 958 - 965. [Abstract] [Full Text] [PDF] M. H. Mangi, W. T. Bellamy, T. M. Grogan, and A. F. List Misleading information about ALIP and VEGF in myelodysplasia Blood, August 15, 2001; 98(4): 1272 - 1273. [Full Text] [PDF] R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020